We are live on
!
Find out more
CCM
Cadence Capital Management Portfolio holdings
AUM
$415M
1-Year Est. Return
11.01%
This Fund
S&P 500
This Quarter
Est. Return
+5.16%
1 Year Est. Return
-11.01%
3 Year Est. Return
+0.72%
5 Year Est. Return
+39.08%
10 Year Est. Return
–
AUM
$1.37B
AUM Growth
+$44.5M
(+3.4%)
Cap. Flow
-$9.6M
Cap. Flow
% of AUM
-0.7%
Top 10 Holdings %
Top 10 Hldgs %
10.12%
Holding
687
New
99
Increased
230
Reduced
280
Closed
72
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$12.2M |
| 2 |
Gilead Sciences
GILD
|
+$11.6M |
| 3 |
ConocoPhillips
COP
|
+$5.98M |
| 4 |
Morgan Stanley
MS
|
+$5.54M |
| 5 |
Capri Holdings
CPRI
|
+$3.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$11.9M |
| 2 |
American International
AIG
|
+$11.1M |
| 3 |
Texas Instruments
TXN
|
+$9.03M |
| 4 |
Prudential Financial
PRU
|
+$7.31M |
| 5 |
General Motors
GM
|
+$6.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 15.46% |
| 2 | Industrials | 14.03% |
| 3 | Technology | 11.99% |
| 4 | Healthcare | 11.73% |
| 5 | Consumer Staples | 11.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
WBA
301
DELISTED
Walgreens Boots Alliance
WBA
| $1.03M | 0.08% |
12,837
+4,846
| +61% | +$395K |
|
302
PDF Solutions
PDFS
$2.1B
| $1.03M | 0.08% |
56,523
-393
| -0.7% | -$6.4K |
|
303
Motorcar Parts of America
MPAA
$261M
| $1.02M | 0.07% |
35,616
+16,510
| +86% | +$464K |
|
|
VASC
304
DELISTED
Vascular Solutions Inc
VASC
| $1.02M | 0.07% |
21,235
-150
| -0.7% | -$6.99K |
|
305
CEVA Inc
CEVA
$974M
| $1.02M | 0.07% |
29,111
-200
| -0.7% | -$6.2K |
|
306
CRA International
CRAI
$1.15B
| $1.01M | 0.07% |
38,076
-9,814
| -20% | -$262K |
|
|
FFWM
307
DELISTED
First Foundation Inc
FFWM
| $1.01M | 0.07% |
81,634
-578
| -0.7% | -$6.89K |
|
|
MIK
308
DELISTED
Michaels Stores, Inc
MIK
| $1M | 0.07% |
41,485
-34,725
| -46% | -$889K |
|
|
FNGN
309
DELISTED
Financial Engines, Inc.
FNGN
| $1M | 0.07% |
+33,710
| New | +$980K |
|
310
Willdan Group
WLDN
$1.14B
| $1M | 0.07% |
57,054
-14,395
| -20% | -$207K |
|
|
NP
311
DELISTED
Neenah, Inc. Common Stock
NP
| $1M | 0.07% |
12,672
-82
| -0.6% | -$6.29K |
|
|
PXD
312
DELISTED
Pioneer Natural Resource Co.
PXD
| $994K | 0.07% |
+5,355
| New | +$911K |
|
313
Mettler-Toledo International
MTD
$28.5B
| $991K | 0.07% |
2,360
-114
| -5% | -$45.3K |
|
|
HZN
314
DELISTED
Horizon Global Corporation
HZN
| $989K | 0.07% |
49,603
-13,106
| -21% | -$202K |
|
|
PETX
315
DELISTED
Aratana Therapeutics, Inc.
PETX
| $989K | 0.07% |
+105,675
| New | +$878K |
|
316
Amazon
AMZN
$2.93T
| $980K | 0.07% |
23,400
+6,200
| +36% | +$237K |
|
317
Barrett Business Services
BBSI
$990M
| $979K | 0.07% |
78,960
-6,040
| -7% | -$68.2K |
|
318
Darden Restaurants
DRI
$23.9B
| $977K | 0.07% |
15,926
+2,925
| +22% | +$181K |
|
319
Corcept Therapeutics
CORT
$11.9B
| $971K | 0.07% |
149,399
+78,491
| +111% | +$456K |
|
320
Kadant
KAI
$3.94B
| $971K | 0.07% |
18,629
-125
| -0.7% | -$6.67K |
|
|
BSTC
321
DELISTED
BioSpecifics Technologies Corp.
BSTC
| $970K | 0.07% |
21,249
-149
| -0.7% | -$5.98K |
|
|
NTRI
322
DELISTED
NutriSystem, Inc.
NTRI
| $967K | 0.07% |
32,567
-2,248
| -6% | -$63.4K |
|
323
Hasbro
HAS
$13B
| $959K | 0.07% |
12,094
-439
| -4% | -$35.7K |
|
324
State Street
STT
$51.7B
| $958K | 0.07% |
13,759
-43,229
| -76% | -$2.83M |
|
325
Medifast
MED
$140M
| $954K | 0.07% |
+25,235
| New | +$905K |
|
Similar funds
MGAI
FA
LWS
VCP
AIM
F
CPF
IA
Cadence Capital Management's Q3 2016 Portfolio in Review
As of Q3 2016, Cadence Capital Management held 687 positions worth $1.37B, up 3.4% from $1.33B the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Cadence Capital Management's Q3 2016 filing shows 99 new, 230 increased, 280 reduced and 72 closed positions. Its largest new stake was Bristol-Myers Squibb: 190,283 shares worth $10.3M. The largest sale was Apple, an estimated $11.9M.
By sector, the portfolio is most concentrated in Financials at 15% of assets, down from 16% a quarter earlier, followed by Industrials and Technology.
- Cadence Capital Management's largest Q3 2016 buy was Bristol-Myers Squibb: 190,283 shares worth $10.3M.
- Cadence Capital Management added most to Gilead Sciences in Q3 2016, an estimated $11.6M increase.
- Cadence Capital Management's biggest Q3 2016 reduction was Apple, cutting an estimated $11.9M.
- Cadence Capital Management fully exited American International in Q3 2016, selling an estimated $11.1M.
- Cadence Capital Management's ten largest holdings make up 10% of its $1.37B portfolio in Q3 2016.
- Cadence Capital Management opened 99 new positions and closed 72 in Q3 2016.
- Cadence Capital Management's portfolio value rose 3.4% quarter-over-quarter to $1.37B.
Based on Cadence Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.